Skip to main content

Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs

101kviews
Editorial22 May 2017
Editorial: Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs
Umberto Malapelleand Pierlorenzo Pallante

The advent of Precision Medicine and Predictive Molecular Pathology ledto a revolution in clinical management of patients with Non Small Cell Lung Cancer.The discovery of oncogene addiction allowed the development of targeted therapies that represent newer therapeutic options reserved to those patients harbouring specific gene alterations, such as EGFR mutations, ALK and ROS1 translocations. (Lazzari et al; 2017. Sullivan et al; 2016; Tran et al; 2016) In addition, the introduction of immunotherapy, with anti PD - 1 Pembrolizumab, in first line treatment ofNSCLC representsthe best choice forEGFR, ALK and ROS1 wild - type patients expressing PD - L1 on ≥ 50% of neoplastic cells. (Cortinovis et al; 2017)Despite the survival improvement achieved with these new therapeutic options in first line treatment, about 30% of patients do not obtain a tumor response. (Lazzari et al; 2017) Moreover, those patients, initially sensitive to these treatments, acquire resistance and develop tumor progression.Approximately 60% of the patients progressing from first line therapy receivingfurther systemic treatment in the second line setting. (Cortinovis et al; 2016. Lazzari et al 2017) Also in second line, the armamentarium for the treatment of patients with NSCLC, includes a pletora of new drugs, such as immune checkpoint inhibitors (Pembrolizumab, Nivolumab), (Cortinovis et al 2016) third generation Tyrosine Kinase Inhibitors (Osimertinib) (Molina-Vila et al; 2016. Zugazagoitia et al; 2017)and antiangiogenic agents (Nintedanib and Ramucirumab). (Correales L et al; 2017. Manzo et al; 2017)

This exciting therapeutic scenario for NSCLC patients still has unsolved questions and challenging issues, in particular regarding the optimal selection of the patient populationthroughthe individualization of the correct methodology and biological source of material (tissues vs liquid biopsy)for clinical relevant biomarkers assessment. (Molina-Vila et al 2016)Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated.

Taken together, the papers published in Research Topic "Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs"represent a critical discussionfocused on the older therapies and the historical development of second line, putting into perspective the new agents available in clinical practice, defining their importance from a clinical point of view, but also to consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena, to support the oncologist to design the best therapeutic strategies for NSCLC patients.

2,231 views

REVIEW
5 April 2017
Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib
Jon Zugazagoitia, 5 more and Luis Paz-Ares

6,033 views

11 citations

In contrast to the established role of epidermal growth factor receptor (EGFR) inhibitors for the first-line treatment of patients with non-small cell lung cancer (NSCLC) harboring activating EGFR mutations, the role of EGFR blockade and of EGFR molecular testing in the second-line treatment remains less clear. The irreversible pan-ErbB family inhibitor afatinib (Gi(l)otrif®) was recently FDA- and EMA-approved for the second-line treatment of NSCLC with squamous cell histology irrespective of the EGFR mutational status (LUX-Lung 8). Contrariwise, results from the TAILOR and DELTA trials among retrospective biomarker analyses show the predictive value of the EGFR mutational status for efficacy of reversible EGFR inhibitors also as a second-line therapy. This mini review critically summarizes the current role of EGFR targeting strategies in the second-line treatment of NSCLC with special respect to afatinib in light of emerging T790M-specific EGFR and immune check point inhibitors. The review also emphasizes the urgent need for reliable biomarkers to guide therapeutic decision making and outlines prospective changes to the second-line landscape with some of the current second-line treatment concepts likely to be moved to the first-line.

6,124 views

13 citations

REVIEW
18 January 2017
Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
Ivana Sullivanand David Planchard
Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor (EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant non-small cell lung cancer (NSCLC). First-generation EGFR TKIs, binding competitively and reversibly to the ATP-binding site of the EGFR tyrosine kinase domain, have resulted in a significant improvement in outcome for NSCLC patients with activating EGFR mutations (L858R and Del19). However, after a median duration of response of ~12 months, all patients develop tumor resistance and in over half of these patients this is due to the emergence of the EGFR T790M resistance mutation. The second-generation EGFR/HER TKIs were developed to treat resistant disease, targeting not only T790M but EGFR activating mutations and wild-type EGFR. Although they exhibited promising anti-T790M activity in the laboratory, their clinical activity among T790M+ NSCLC was poor mainly because of dose-limiting toxicity due to simultaneous inhibition of wild-type EGFR. The third-generation EGFR TKIs selectively and irreversibly target EGFR T790M and activating EGFR mutations, showing promising efficacy in NSCLC resistant to the first- and second-generation EGFR TKIs. They also appear to have lower incidences of toxicity due to the limited inhibitory effect on wild-type EGFR. Currently, the first-generation gefitinib and erlotinib and second-generation afatinib have been approved for first-line treatment of metastatic NSCLC with activating EGFR mutations. Among the third-generation EGFR TKIs, osimertinib is today the only drug approved by the FDA and the EMA to treat metastatic EGFR T790M NSCLC patients who have progressed on or after EGFR TKI therapy. In this review we summarize the available post-progression therapies including third-generation EGFR inhibitors and combination treatment strategies for treating patients with NSCLC harboring EGFR mutations, and address the known mechanisms of resistance.

32,425 views

121 citations

REVIEW
23 January 2017
Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer
Chiara Lazzari, 6 more and Vanesa Gregorc

10,122 views

40 citations

Liquid Biopsy in Non-Small Cell Lung Cancer
MINI REVIEW
23 December 2016
Liquid Biopsy in Non-Small Cell Lung Cancer
Miguel A. Molina-Vila, 20 more and Rafael Rosell
Liquid biopsy analyses are already incorporated in the routine clinical practice in many hospitals and oncology departments worldwide, improving the selection of treatments and monitoring of lung cancer patients. Although they have not yet reached its full potential, liquid biopsy-based tests will soon be as widespread as "standard" biopsies and imaging techniques, offering invaluable diagnostic, prognostic and predictive information. This review summarizes the techniques available for the isolation and analysis of circulating-free DNA and RNA, exosomes, tumor-educated platelets and CTCs from the blood of cancer patient, presents the methodological challenges associated with each of these materials and discusses the clinical applications of liquid biopsy testing in lung cancer.

11,841 views

64 citations

REVIEW
19 December 2016
Focus on Nintedanib in NSCLC and Other Tumors
Anna Manzo, 5 more and Alessandro Morabito

5,859 views

15 citations